36194-82-8

Basic information

• Product Name: 5-BROMO-2-HYDROXY-3-METHYLBENZENECARBOXYLIC ACID
• Synonyms: 5-BROMO-2-HYDROXY-3-METHYLBENZENECARBOXYLIC ACID;5-BROMO-2-HYDROXY-3-METHYLBENZOIC ACID;5-Bromo-3-methylsalicylic acid, 5-Bromo-2-hydroxy-m-toluic acid
• CAS NO: 36194-82-8
• Molecular Formula: C₈H₇BrO₃
• Molecular Weight: 231.04
• Mol File: 36194-82-8.mol
• Article Data: 4

Chemical Properties

• Melting Point: 231-234
• Boiling Point: 340.1 °C at 760 mmHg
• Flash Point: 159.5 °C
• Appearance: /
• Density: 1.739 g/cm³
• Vapor Pressure: 3.4E-05mmHg at 25°C
• Refractive Index: 1.635
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 5-BROMO-2-HYDROXY-3-METHYLBENZENECARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2-HYDROXY-3-METHYLBENZENECARBOXYLIC ACID(36194-82-8)
• EPA Substance Registry System: 5-BROMO-2-HYDROXY-3-METHYLBENZENECARBOXYLIC ACID(36194-82-8)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 36194-82-8(Hazardous Substances Data)

Usage

General Description

5-Bromo-2-hydroxy-3-methylbenzenecarboxylic acid is a chemical compound with the molecular formula C8H7BrO3. It is a derivative of benzoic acid and contains a bromine atom, hydroxyl group, and a methyl group. 5-BROMO-2-HYDROXY-3-METHYLBENZENECARBOXYLIC ACID is commonly used in organic synthesis and pharmaceutical research, particularly as a starting material for the synthesis of other chemicals and pharmaceuticals. It has potential applications in the development of anti-inflammatory and analgesic drugs due to its structural similarities with certain nonsteroidal anti-inflammatory drugs. Additionally, it has been studied for its potential antioxidant and antimicrobial properties, making it a valuable compound for various research and development applications.

InChI:InChI=1/C8H7BrO3/c1-4-2-5(9)3-6(7(4)10)8(11)12/h2-3,10H,1H3,(H,11,12)

Upstream product

• 83-40-9 3-methylsalicylic acid 
• 67-66-3 chloroform 
• 7726-95-6 bromine 
• 64-19-7 acetic acid 

Downstream Products

• 40912-71-8 5-bromo-3-methylsalicylic acid methyl ester 
• 20294-50-2 4-bromo-2-methyl-6-nitrophenol 
• 722497-32-7 methyl 5-bromo-2-methoxy-3-methyl-benzoate 
• 1257883-70-7 5-bromo-2-hydroxy-3-methyl-N-(quinolin-3-yl)benzamide 
• 159121-84-3 5-bromo-2-methoxy-3-methyl-benzoic acid 
• 1427407-43-9 N-(2,6-difluoro-3-hydroxyphenyl)-5-(3-fluorophenyl)-2-methoxy-3-methylbenzamide 
• 1427407-44-0 2,4-difluoro-3-[[5-(3-fluorophenyl)-2-methoxy-3-methylphenyl]methylamino]phenol 
• 1427407-45-1 ethyl 2-[2,4-difluoro-3-[[5-(3-fluorophenyl)-2-methoxy-3-methyl-phenyl]methylamino]phenoxy]acetate 
• 1427406-20-9 C₂₃H₂₀F₃NO₄ 
• 1427407-46-2 C₂₄H₂₂F₃NO₄ 

Relevant articles and documents

Live-Cell Protein Modification by Boronate-Assisted Hydroxamic Acid Catalysis

Selective methods for introducing protein post-translational modifications (PTMs) within living cells have proven valuable for interrogating their biological function. In contrast to enzymatic methods, abiotic catalysis should offer access to diverse and new-to-nature PTMs. Herein, we report the boronate-assisted hydroxamic acid (BAHA) catalyst system, which comprises a protein ligand, a hydroxamic acid Lewis base, and a diol moiety. In concert with a boronic acid-bearing acyl donor, our catalyst leverages a local molarity effect to promote acyl transfer to a target lysine residue. Our catalyst system employs micromolar reagent concentrations and affords minimal off-target protein reactivity. Critically, BAHA is resistant to glutathione, a metabolite which has hampered many efforts toward abiotic chemistry within living cells. To showcase this methodology, we installed a variety of acyl groups inE. colidihydrofolate reductase expressed within human cells. Our results further establish the well-known boronic acid-diol complexation as abona fidebio-orthogonal reaction with applications in chemical biology and in-cell catalysis.

NK-1 AND SEROTONIN TRANSPORTER INHIBITORS

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating disorders associated with an excess or imbalance of tachykinins or serotonin or both.